Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of Everolimus, a generic oncology drug, in the Canadian market through its subsidiary Nora Pharma Inc. Everolimus, a generic equivalent of Afinitor®, is designed to treat multiple conditions including advanced renal cell carcinoma, HER2-negative breast cancer, neuroendocrine tumors, and subependymal giant cell astrocytoma.
The drug is available in 2.5 mg, 5 mg, and 10 mg strengths in 30-tablet blister packs. The global Everolimus market, valued at $2.5 billion in 2023, is projected to reach $4.8 billion by 2032 with a 7.1% CAGR. The Canadian market segment represents approximately 2.2% of the global market and is growing at a 6.4% CAGR.
Sunshine Biopharma (NASDAQ:SBFM) ha annunciato il lancio di Everolimus, un farmaco oncologico generico, nel mercato canadese tramite la sua controllata Nora Pharma Inc. Everolimus, equivalente generico di Afinitor®, è indicato per il trattamento di diverse patologie tra cui carcinoma renale avanzato, carcinoma mammario HER2-negativo, tumori neuroendocrini e astrocitoma gigante a cellule subependimali.
Il farmaco è disponibile in dosaggi da 2,5 mg, 5 mg e 10 mg in confezioni blister da 30 compresse. Il mercato globale di Everolimus, valutato 2,5 miliardi di dollari nel 2023, è previsto raggiungere 4,8 miliardi di dollari entro il 2032 con un tasso di crescita annuale composto (CAGR) del 7,1%. Il mercato canadese rappresenta circa il 2,2% del mercato globale e cresce con un CAGR del 6,4%.
Sunshine Biopharma (NASDAQ:SBFM) ha anunciado el lanzamiento de Everolimus, un medicamento oncológico genérico, en el mercado canadiense a través de su subsidiaria Nora Pharma Inc. Everolimus, equivalente genérico de Afinitor®, está diseñado para tratar múltiples condiciones, incluyendo carcinoma renal avanzado, cáncer de mama HER2-negativo, tumores neuroendocrinos y astrocitoma gigante de células subependimarias.
El medicamento está disponible en presentaciones de 2.5 mg, 5 mg y 10 mg en blísteres de 30 tabletas. El mercado global de Everolimus, valorado en $2.5 mil millones en 2023, se proyecta que alcance $4.8 mil millones para 2032 con una tasa de crecimiento anual compuesta (CAGR) del 7.1%. El segmento del mercado canadiense representa aproximadamente el 2.2% del mercado global y crece a un CAGR del 6.4%.
Sunshine Biopharma (NASDAQ:SBFM)는 자회사 Nora Pharma Inc.를 통해 캐나다 시장에 에버로리무스(Everolimus)라는 제네릭 항암제를 출시했다고 발표했습니다. 에버로리무스는 Afinitor®의 제네릭 제품으로, 진행성 신세포암, HER2 음성 유방암, 신경내분비종양, 아교세포종 등 다양한 질환 치료를 위해 개발되었습니다.
이 약물은 2.5mg, 5mg, 10mg 용량으로 30정 블리스터 팩 형태로 제공됩니다. 2023년 기준 25억 달러 규모인 글로벌 에버로리무스 시장은 연평균 성장률(CAGR) 7.1%로 2032년까지 48억 달러에 이를 것으로 예상됩니다. 캐나다 시장은 전 세계 시장의 약 2.2%를 차지하며 연평균 성장률 6.4%로 성장 중입니다.
Sunshine Biopharma (NASDAQ:SBFM) a annoncé le lancement d'Everolimus, un médicament oncologique générique, sur le marché canadien via sa filiale Nora Pharma Inc. Everolimus, équivalent générique d'Afinitor®, est destiné au traitement de plusieurs affections, notamment le carcinome rénal avancé, le cancer du sein HER2 négatif, les tumeurs neuroendocrines et l’astrocytome géant à cellules sous-épendymaires.
Le médicament est disponible en dosages de 2,5 mg, 5 mg et 10 mg sous forme de plaquettes de 30 comprimés. Le marché mondial de l’Everolimus, évalué à 2,5 milliards de dollars en 2023, devrait atteindre 4,8 milliards de dollars d’ici 2032 avec un taux de croissance annuel composé (TCAC) de 7,1 %. Le segment canadien représente environ 2,2 % du marché mondial et connaît une croissance à un TCAC de 6,4 %.
Sunshine Biopharma (NASDAQ:SBFM) hat die Markteinführung von Everolimus, einem generischen Onkologiemedikament, auf dem kanadischen Markt über seine Tochtergesellschaft Nora Pharma Inc. bekannt gegeben. Everolimus, ein generisches Pendant zu Afinitor®, ist zur Behandlung verschiedener Erkrankungen wie fortgeschrittenem Nierenzellkarzinom, HER2-negativem Brustkrebs, neuroendokrinen Tumoren und subependymalem Riesenzell-Astrozytom entwickelt worden.
Das Medikament ist in Stärken von 2,5 mg, 5 mg und 10 mg in Blisterpackungen mit 30 Tabletten erhältlich. Der globale Everolimus-Markt, der im Jahr 2023 mit 2,5 Milliarden US-Dollar bewertet wurde, wird voraussichtlich bis 2032 auf 4,8 Milliarden US-Dollar mit einer jährlichen Wachstumsrate (CAGR) von 7,1 % anwachsen. Der kanadische Markt macht etwa 2,2 % des globalen Marktes aus und wächst mit einer CAGR von 6,4 %.
- Launch of generic Everolimus in Canadian market expands product portfolio
- Entry into $2.5 billion global market with 7.1% CAGR potential
- Multiple approved indications across various types of cancer increases market potential
- Canadian market segment represents only 2.2% of global market
- Will face competition from existing generic alternatives
FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Everolimus in the Canadian generic prescription drugs market.
Everolimus is a generic equivalent of the brand name Afinitor®. Everolimus is indicated for the treatment of (i) advanced renal cell carcinoma, (ii) breast cancer in post-menopausal women with advanced HER2-negative genotype, (iii) progressive well or moderately differentiated neuroendocrine tumors of pancreatic, gastrointestinal or lung origin, and (iv) subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Nora Pharma's Everolimus is available in strengths of 2.5 mg, 5 mg, and 10 mg and comes in blister packs of 30 tablets.
According to DATAINTELO, the global Everolimus market was valued at
"Our presence in the industry is propelled by a relentless pursuit of progress," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "Through continued investment in cutting-edge technologies, breakthrough research, and strategic partnerships, we are advancing solutions that create lasting impact for patients," he added.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and more than 15 additional drugs scheduled to be launched in remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
What is the market size for Everolimus and how much is it expected to grow?
What medical conditions does SBFM's Everolimus treat?
What dosage strengths is SBFM's Everolimus available in?
What is the size of Everolimus market in Canada for SBFM?
